)
Visual
test
Shenzhen New Industries Biomedical Engineering
Shenzhen New Industries Biomedical Engineering (300832) investor relations material
Shenzhen New Industries Biomedical Engineering Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Q3 2025 revenue reached ¥1.24 billion, up 3.28% year-over-year; YTD revenue was ¥3.43 billion, up 0.39% year-over-year.
Net profit attributable to shareholders for Q3 was ¥434 million, down 9.72% year-over-year; YTD net profit was ¥1.20 billion, down 12.92% year-over-year.
Domestic main business revenue declined 10.95% YTD, while overseas main business revenue grew 21.07% YTD.
High-end equipment sales, especially MAGLUMI X8 and X10, showed stable growth; SATLARS T8 automation line achieved 158 global installations YTD.
Financial highlights
Q3 operating cash flow was ¥1.06 billion, up 11.08% year-over-year.
Basic and diluted EPS for Q3 were ¥0.5520, down 9.73% year-over-year; YTD EPS was ¥1.5334, down 12.92%.
Gross margin and operating income details not explicitly stated, but profit margins declined.
Total assets at Q3-end were ¥9.58 billion, down 0.44% from year-end 2024.
Shareholders’ equity increased 1.96% to ¥8.74 billion.
Outlook and guidance
Overseas reagent business revenue grew 37.23% YTD, supporting future international expansion.
Company aims to meet full-year automation line installation targets, leveraging new product launches.
Domestic market revenue decline impact on profit?
Investment cash flow volatility drivers?
High-end product sales contribution to growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Shenzhen New Industries Biomedical Engineering earnings date
Q4 202528 Apr, 2026
Shenzhen New Industries Biomedical Engineering
Next Shenzhen New Industries Biomedical Engineering earnings date
Q4 202528 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Shenzhen New Industries Biomedical Engineering Co., Ltd., often referred to as Snibe, is a prominent bio-medical company based in Shenzhen, China. Founded in 1995, the company specializes in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents. Snibe offers a range of products, including immunoassay systems, clinical chemistry equipment, molecular diagnostics, point-of-care testing solutions, lab automation, and integrated systems. These products are utilized by hospitals and laboratories both within China and internationally. The company is headquartered in Shenzhen, Guangdong, and its shares are listed on the Shenzhen Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage